TITLE

Aspirin and Clopidogrel Resistance

AUTHOR(S)
Michos, Erin D.; Ardehali, Reza; Blumenthal, Roger S.; Lange, Richard A.; Ardehali, Hossein
PUB. DATE
April 2006
SOURCE
Mayo Clinic Proceedings;Apr2006, Vol. 81 Issue 4, p518
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Despite aspirin's and clopidogrel's proven benefit in reducing cardiovascular (CV) events, recurrent CV events still occur in patients receiving antiplatelet therapy. Many of these patients are resistant or only partially responsive to the antiplatelet effects of aspirin and clopidogrel, as determined by standard platelet assays. However, current clinical guidelines do not support routine screening for aspirin or clopidogrel resistance, in part because determination of the most appropriate screening test has not been established. This review attempts to (1) describe the phenomena of clinical aspirin and clopidogrel resistance (ie, treatment failure), (2) discuss the complexity of defining and identifying aspirin and clopidogrel resistance, (3) identify factors that may be responsible for aspirin and clopidogrel resistance, (4) outline several standard platelet function assays and their limitations, and (5) describe potential new antiplatelet therapies that may benefit aspirin- or clopdogrel-resistant patients.
ACCESSION #
20449855

 

Related Articles

  • Administration of a Glycoprotein IIb/IIIa Receptor Blocker with a Thienopyridine Derivative Does Not Increase the Risk of Thrombocytopenia. Silver, Kevin H.; Newman, Isadore; Rohr, Susan M.; Johnson, Jeremy; Josephson, Richard A. // Ohio Journal of Science;Sep2005, Vol. 105 Issue 4, p74 

    The combination of aspirin, a thienopyridine derivative, and a glycoprotein IIb/IIIa receptor inhibitor has become standard therapy for patients undergoing percutaneous coronary intervention (PCI). Recent studies have shown an increased incidence of thrombocytopenia in those patients receiving a...

  • Anagrelide is an effective platelet-lowering agent, but its role in the treatment of essential thrombocythaemia has yet to be fully determined.  // Drugs & Therapy Perspectives;Nov2006, Vol. 22 Issue 11, p1 

    Anagrelide, an oral imidazoquinazoline agent, has platelet-lowering activity. In nonrandomised trials, anagrelide reduced platelet counts in most patients with essential thrombocythaemia, including treatment-naive patients and those refractory to previous cytoreductive therapy. In a randomised...

  • Use of linezolid in infants and children: a retrospective multicentre study of the Italian Society for Paediatric Infectious Diseases. Garazzino, Silvia; Krzysztofiak, Andrzej; Esposito, Susanna; Castagnola, Elio; Plebani, Alessandro; Galli, Luisa; Cellini, Monica; Lipreri, Rita; Scolfaro, Carlo; Bertaina, Chiara; Calitri, Carmelina; Bozzola, Elena; Lancella, Laura; Quondamcarlo, Anna; Bosis, Samantha; Pugni, Lorenza; Losurdo, Giuseppe; Soresina, Annarosa; De Gaudio, Marina; Mariotti, Ilaria // Journal of Antimicrobial Chemotherapy (JAC);Oct2011, Vol. 66 Issue 10, p2393 

    Objectives Because of the spread of drug-resistant Gram-positive bacteria, the use of linezolid for treating severe infections is increasing. However, clinical experience in the paediatric population is still limited. We undertook a multicentre study to analyse the use of linezolid in children....

  • A unified definition of clinical resistance/intolerance to hydroxyurea in essential thrombocythemia: results of a consensus process by an international working group. Barosi, G.; Besses, C.; Birgegard, G.; Briere, J.; Cervantes, F.; Finazzi, G.; Gisslinger, H.; Griesshammer, M.; Gugliotta, L.; Harrison, C.; Hasselbalch, H.; Lengfelder, E.; Reilly, J. T.; Michiels, J. J.; Barbui, T. // Leukemia (08876924);Feb2007, Vol. 21 Issue 2, p277 

    A widely accepted definition of resistance or intolerance to hydroxyurea (HU) in patients with essential thrombocythemia (ET) is lacking. An international working group (WG) was convened to develop a consensus formulation of clinically significant criteria for defining resistance/intolerance to...

  • Statin neurotoxicity visualised in bioassay.  // Reactions Weekly;4/20/2013, Issue 1449, p1 

    The article focuses on the neurotoxicity of statins observed from bioassay, which has been associated to those patients treated with statins who experienced reversible neurocognitive adverse effects like memory loss or fuzzy thinking.

  • Antiplatelet Agents in Microvascular Surgery. Laha, Ranjit K.; Dujovny, Manuel; Decastro, Samuel; Phillips, John; Barrionuevo, Pedro J. // Vascular Surgery;Jan/Feb1980, Vol. 14 Issue 1, p39 

    Evaluates the role of aspirin, dipyridamole and prostaglandin to assess their effects in microvascular anastomosis in rabbits. Use of scanning electron microscopy; Role of the drugs in the formation of red blood cell platelet clumps; Issues concerning microvascular reconstructive surgery.

  • Anagrelide: A Review of its Use in the Management of Essential Thrombocythaemia. Wagstaff, Antona J.; Keating, Gillian M. // Drugs;2006, Vol. 66 Issue 1, p111 

    Anagrelide (Agrylin®, Xagrid®) is an oral imidazoquinazoline agent which is indicated in Europe for the reduction of elevated platelet counts in at-risk patients with essential thrombocythaemia who are intolerant of or refractory to their current therapy, and in the US for the reduction of...

  • Life-threatening thrombocytopenia associated with acute Epstein-Barr virus infection in an older adult. Walter, R. B.; Hong, T. C.; Bachli, E. B. // Annals of Hematology;Nov2002, Vol. 81 Issue 11, p672 

    Acute Epstein-Barr virus (EBV) infection commonly induces hematological abnormalities, most notably atypical lymphocytosis ("infectious mononucleosis"). In addition, mild decreases in platelet counts are commonly encountered in uncomplicated cases; however, severe thrombocytopenia is exceedingly...

  • P232 Aspirin resistance in hypertensive patients with coronary artery disease: prevalence, predictors and prognostic value. Alhabil, B; Abid, L; Ben Amor, I; Laroussi, L; Kamoun, S // Cardiovascular Research;Jul2014, Vol. 103 Issue suppl_1, pS41 

    Purpose: we proposed to investigate the aspirin response in hypertensive patients with coronary disease,to determine the prevalence,predictors and the prognostic value of aspirin resistance in this particular population.Methods: 79 patents who had been taken aspirin regulary (100/d) for...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics